Technical Data
K0199-16
KRT13 (Keratin 13, CK13, Keratin, Type I Cytoskeletal 13)
Description:
Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
Peptide ELISA: 1:128,000.
Western Blot: A Band is detected at ~55kD in Human Lung, Skeletal Muscle and Skin lysates (calculated MW of 49.6kDa according to NP_705694.2). Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile 40-50% glycerol, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can

Peptide Blocking:
Corresponding peptide is available for Peptide Blocking studies. See K0199-16-P. Antibody is typically 0.5mg/ml and peptide is supplied as a 100ul pellet. When peptide is reconstituted in 200ul water, the concentration would also be 0.5mg/ml. To start, the best ratio would be 1:1 (molar excess of peptide relative to antibody when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots to be incubated with equal amount of antibody, but one with the antibody pre-adsorbed to the peptide for 20min. Then incubate and develop the two blots in parallel.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug4°C (-20°C Glycerol)Blue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
A synthetic peptide from the C-terminus of aa-TSNASGRRTSDVRRP.
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in Tris saline, pH 7.2, 0.5% BSA, 0.02% sodium azide.
Specificity:
Recognizes human KRT13.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Matta H, Mazzacurati L, Schamus S, Yang T, Sun Q, Chaudhary PM. Kaposi's sarcoma-associated herpesvirus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the IkappaB kinase complex to selectively activate NF-kappaB without JNK activation. J Biol Chem. 2007 Aug 24;282(34):24858-65.